Table 1.
Case | Age (years)/sex | Histology | Cranial irradiation TD | Age (years), latency | WHO grade/histology | Recurrence | Multiple | Ki-67 (%) | Author name, year |
---|---|---|---|---|---|---|---|---|---|
1 |
1/M |
Cerebellar medulloblastoma |
30 Gy to WB, 10.5 Gy to tumor |
12, 11 |
1 |
CR 12 years |
No |
1.8 |
S.Nishio 1998 |
2 |
2/M |
ALL |
24 Gy to WB |
16, 14.5 |
1 |
CR 3 years |
No |
3.7 |
S.Nishio 1998 |
3 |
23/F |
Astrocytoma |
60 Gy to humor |
37, 14 |
1 |
Progression of the primary disease, dead after 22 months |
No |
1.7 |
S.Nishio 1998 |
4 |
17/F |
Ependymoma |
30 Gy to WB and 30 Gy to tumor |
38, 21 |
1 |
CR 3 years |
No |
6.9 |
S.Nishio 1998 |
5 |
10/F |
Medulloblastoma |
30 Gy to WB and 29.5 Gy to tumor |
41.5, 31.5 |
Benign, transitional |
No |
No |
1 |
P.Strojan 2000 |
6 |
11/M |
Medulloblastoma |
31.5 Gy to WB and 24 Gy to tumor |
35, 24 |
Benign, meningotheliomatous |
No |
Yes (3) |
9 |
P.Strojan 2000 |
Benign, transitional |
3 |
||||||||
? |
? |
||||||||
7 |
9/F |
ALL |
10 Gy to WB |
29, 20.5 |
Benign, transitional |
Yes (3) |
Yes (3) |
2 |
P.Strojan 2000 |
13.5 |
ALL, relapse |
24 Gy to WB |
30, 21.5 |
Atypical, transitional |
7 |
||||
31, 22.5 |
Atypical, transitional |
15 |
|||||||
31.5, 23 |
? |
? |
|||||||
8 |
4/M |
ALL |
18 Gy to WB |
13, 9.5 |
Atypical, fibrous |
Yes (1) |
Yes (2) |
15 |
P.Strojan 2000 |
14.5, 11 |
Benign, fibrous |
1 |
|||||||
18.5, 15 |
? |
? |
|||||||
9 |
3/M |
NHL |
19.5 Gy to basal skull |
15.5, 12.5 |
Atypical, fibrous |
No |
No |
3 |
P.Strojan 2000 |
3.5 |
NHL, relapse |
24 Gy to basal skull |
|||||||
10 |
13/M |
Craniopharyngiom |
HD Gy to tumor |
44, 31 |
Atypical |
No |
Yes (3) |
? |
Al-Mefty 2004 |
47, 34 |
Benign, meningotheliomatous |
1 |
|||||||
53, 41 |
? |
? |
|||||||
11 |
12/M |
NHL |
HD Gy to WB |
34, 22 |
Benign, meningotheliomatous |
Yes (1) |
Yes (2) |
3 |
Al-Mefty 2004 |
37, 25 |
? |
? |
|||||||
12 |
3/M |
Medulloblastom |
HD (50 Gy) |
9, 6 |
Clear cell |
Yes (1) |
Yes (NA) |
7 |
Samer KE, 2012 |
13 |
7/F |
AML |
MD (16 Gy) |
14, 7 |
Meningothelial, chordoid |
Yes (1) |
Yes (NA) |
10 |
Samer KE, 2012 |
14 |
5/M |
Ependymoma |
HD (55) |
18, 13 |
Meningothelial |
Yes (1) |
No |
6 |
Samer KE, 2012 |
15 |
7/M |
ALL |
MD (14 Gy) |
16, 9 |
Fibroblastic |
No |
No |
4 |
Samer KE, 2012 |
16 |
2/M |
Medulloblastoma |
HD (50 Gy) |
13, 11 |
Atypical meningotherial, xanthomatou |
Yes (1) |
Yes (NA) |
6.2 |
Samer KE, 2012 |
17 |
7/F |
ALL |
HD (30 Gy) |
17, 10 |
Meningothelial, chordoid |
Yes (2) |
Yes (NA) |
7.2 |
Samer KE, 2012 |
18 |
4/F |
Medulloblastoma |
HD (50 Gy) |
17, 13 |
Meningothelial, fibroblastic |
No |
Yes (2) |
6.9 |
Samer KE, 2012 |
19 |
5/M |
Ependymoma |
HD (55 Gy) |
17, 12 |
Atypical meningothelial, rhabdoid |
Yes (1) |
Yes (NA) |
10.4 |
Samer KE, 2012 |
20 |
2/M |
Ependymoma |
HD (55 Gy) |
10, 8 |
Xanthomatous |
No |
No |
5 |
R.Ijiri 2000 |
21 | 3/M | ALL | 18 Gy to WB | 28, 25 | Benign, meningotheliomatous |
Yes (1) | Yes (3) | 10 |
Current case report |
Benign, meningotheliomatous |
15 |
||||||||
Atypical | 20 |
WB, whole brain; CR, complete remission; ?, no surgical treatment and unknown pathological features; HD, high dose (greater than 20 Gy); M, male; F, female; ALL, acute lymphoblastic leukemia; NHL, non-hodgkin lymphoma; AML, acute myelogenous lymphoma; TD, total dose; NA, not available.